|Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia|
JC Byrd, RR Furman, SE Coutre, IW Flinn, JA Burger, KA Blum, B Grant, ...
New England Journal of Medicine 369 (1), 32-42, 2013
|Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib|
JA Woyach, RR Furman, TM Liu, HG Ozer, M Zapatka, AS Ruppert, L Xue, ...
New England Journal of Medicine 370 (24), 2286-2294, 2014
|Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765|
SEM Herman, AL Gordon, E Hertlein, A Ramanunni, X Zhang, ...
Blood 117 (23), 6287-6296, 2011
|CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability|
BJ Lannutti, SA Meadows, SEM Herman, A Kashishian, B Steiner, ...
Blood 117 (2), 591-594, 2011
|Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib|
JC Byrd, RR Furman, SE Coutre, JA Burger, KA Blum, M Coleman, ...
Blood, blood-2014-10-606038, 2015
|Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival …|
SEM Herman, AL Gordon, AJ Wagner, NA Heerema, W Zhao, JM Flynn, ...
Blood 116 (12), 2078-2088, 2010
|Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial|
S O'Brien, RR Furman, SE Coutre, JP Sharman, JA Burger, KA Blum, ...
The lancet oncology 15 (1), 48-58, 2014
|Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug|
AG Ramsay, AJ Johnson, AM Lee, G Gorgün, R Le Dieu, W Blum, JC Byrd, ...
The Journal of clinical investigation 118 (7), 2427-2437, 2008
|Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia|
JC Byrd, B Harrington, S O’Brien, JA Jones, A Schuh, S Devereux, ...
New England Journal of Medicine 374 (4), 323-332, 2016
|Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes|
JA Dubovsky, KA Beckwith, G Natarajan, JA Woyach, S Jaglowski, ...
Blood 122 (15), 2539-2549, 2013
|Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia|
JC Byrd, TS Lin, JT Dalton, D Wu, MA Phelps, B Fischer, M Moran, ...
Blood 109 (2), 399-404, 2006
|Genetic heterogeneity of diffuse large B-cell lymphoma|
J Zhang, V Grubor, CL Love, A Banerjee, KL Richards, PA Mieczkowski, ...
Proceedings of the National Academy of Sciences 110 (4), 1398-1403, 2013
|The B-cell receptor signaling pathway as a therapeutic target in CLL|
JA Woyach, AJ Johnson, JC Byrd
Blood 120 (6), 1175-1184, 2012
|Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia|
KJ Maddocks, AS Ruppert, G Lozanski, NA Heerema, W Zhao, L Abruzzo, ...
JAMA Oncology 1 (1), 80-87, 2015
|Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells|
X Song, HP Lin, AJ Johnson, PH Tseng, YT Yang, SK Kulp, CS Chen
Journal of the National Cancer Institute 94 (8), 585-591, 2002
|Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease|
TS Lin, AS Ruppert, AJ Johnson, B Fischer, NA Heerema, LA Andritsos, ...
Journal of Clinical Oncology 27 (35), 6012-6018, 2009
|Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy|
JA Woyach, K Smucker, LL Smith, A Lozanski, Y Zhong, AS Ruppert, ...
Blood 123 (12), 1810-1817, 2014
|Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia|
R Lapalombella, Q Sun, K Williams, L Tangeman, S Jha, Y Zhong, ...
Blood 120 (23), 4621-4634, 2012
|Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma|
D Chiron, M Di Liberto, P Martin, X Huang, J Sharman, P Blecua, ...
Cancer discovery 4 (9), 1022-1035, 2014
|Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia|
MA Phelps, TS Lin, AJ Johnson, E Hurh, DM Rozewski, KL Farley, D Wu, ...
Blood 113 (12), 2637-2645, 2009